光生物调节疗法治疗年龄相关性黄斑变性的大软性玻璃膜疣和玻璃膜疣性色素上皮脱离:一项单中心前瞻性先导研究
这项单中心前瞻性先导研究纳入20只患有大软性玻璃膜疣和/或玻璃膜疣性色素上皮脱离的干性年龄相关性黄斑变性眼,采用LumiThera Valeda光递送系统每周治疗两次、持续5周。第6个月随访时最佳矫正视力平均提高5.5个字母(P=0.007),玻璃膜疣体积减少0.11 mm³(P=0.03),中心玻璃膜疣厚度减少17.05 µm(P=0.01),地图样萎缩面积增加0.06 mm²(P=0.01)。作者认为光生物调节可能为这类患者提供一种有效的治疗选择,并可能潜在延缓疾病的自然病程。
要点
- 20只干性年龄相关性黄斑变性眼接受光生物调节治疗,每周两次共5周。
- 第6个月最佳矫正视力平均提高5.5个字母(P=0.007),玻璃膜疣体积减少0.11 mm³(P=0.03)。
- 地图样萎缩面积增加0.06 mm²(P=0.01),1例患者在M6出现玻璃膜疣性色素上皮脱离破裂。
核心结论
- 作者认为患者视力和解剖学改善支持既往关于光生物调节的报道,光生物调节可能为大片软性玻璃膜疣和玻璃膜疣性色素上皮脱离的年龄相关性黄斑变性提供一种有效的治疗选择,并可能潜在延缓疾病的自然病程。
研究设计与样本
- 单中心前瞻性先导研究,纳入20只患有大软性玻璃膜疣和/或玻璃膜疣性色素上皮脱离的年龄相关性黄斑变性眼,使用LumiThera Valeda光递送系统治疗,每周两次、持续5周。
主要发现
- 第6个月最佳矫正视力平均提高5.5个字母(P=0.007)。
- 视网膜敏感度下降0.1 dB(P=0.17),平均注视稳定性提高0.45%(P=0.72)。
- 玻璃膜疣体积减少0.11 mm³(P=0.03),中心玻璃膜疣厚度平均减少17.05 µm(P=0.01)。
- 1例患者在光生物调节治疗后第6个月出现玻璃膜疣性色素上皮脱离破裂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate visual acuity and morphologic changes after photobiomodulation (PBM) for patients affected with large soft drusen and/or drusenoid pigment epithelial detachment associated with dry age-related macular degeneration. METHOD: Twenty eyes with large soft drusen and/or drusenoid pigment epithelial detachment age-related macular degeneration were included and treated using the LumiThera Valeda Light Delivery System. All patients underwent two treatments per week for 5 weeks. Outcome measures included best-corrected visual acuity, microperimetry-scotopic testing, drusen volume, central drusen thickness, and quality of life score at baseline and month 6 (M6) follow-up. Data of best-corrected visual acuity, drusen volume, and central drusen thickness were also recorded at week 5 (W5). RESULTS: Best-corrected visual acuity significantly improved at M6 with a mean score gain of 5.5 letters ( P = 0.007). Retinal sensitivity decreased by 0.1 dB ( P = 0.17). The mean fixation stability increased by 0.45% ( P = 0.72). Drusen volume decreased by 0.11 mm 3 ( P = 0.03). Central drusen thickness was reduced by a mean of 17.05 µ m ( P = 0.01). Geographic atrophy area increased by 0.06 mm 2 ( P = 0.01) over a 6-month follow-up, and quality of life score increased by 3,07 points on average ( P = 0.05). One patient presented a drusenoid pigment epithelial detachment rupture at M6 after PBM treatment. CONCLUSION: The visual and anatomical improvements in our patients support previous reports on PBM. PBM may provide a valid therapeutic option for large soft drusen and drusenoid pigment epithelial detachment age-related macular degeneration and may potentially slow the natural course of the disease.
引用
- Benlahbib M, Cohen SY, Torrell N, et al. PHOTOBIOMODULATION THERAPY FOR LARGE SOFT DRUSEN AND DRUSENOID PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION: A Single-Center Prospective Pilot Study. Retina. 2023. PMID: 37027819. doi:10.1097/IAE.0000000000003805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。